Brief: Ipsen Receives CHMP Positive Opinions For Iqirvo And Kayfanda

Ipsen SA

26/07/2024 11:49

July 26 (Reuters) - Ipsen SA  IPN.PA :
    * IPSEN RECEIVES CHMP POSITIVE OPINIONS FOR IQIRVO®
(ELAFIBRANOR)
IN PRIMARY BILIARY CHOLANGITIS AND KAYFANDA® (ODEVIXIBAT) IN
ALAGILLE SYNDROME, TWO RARE CHOLESTATIC LIVER DISEASES
    * FINAL EUROPEAN COMMISSION DECISION FOR BOTH MEDICINES
EXPECTED
IN Q3 2024

Source text for Workspace:  urn:newsml:reuters.com:*:nGNEbNjr7m
Further company coverage:  IPN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))